WallStSmart

Churchill Capital Corp XI (CCXI)vsEQV Ventures Acquisition Corp. II (EVAC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

EVAC leads profitability with a 0.0% profit margin vs 0.0%. EVAC earns a higher WallStSmart Score of 32/100 (F).

CCXI

Avoid

24

out of 100

Grade: F

Growth: 4.3Profit: 4.0Value: 5.0Quality: 6.0
Piotroski: 2/9

EVAC

Avoid

32

out of 100

Grade: F

Growth: 4.3Profit: 3.5Value: 4.7Quality: 6.0
Piotroski: 2/9

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCXI0 strengths · Avg: 0/10

No standout strengths identified

EVAC0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

CCXI4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$805.98M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
4.7%3/10

ROE of 4.7% — below average capital efficiency

EVAC4 concerns · Avg: 3.8/10
P/E RatioValuation
31.0x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$597.92M3/10

Smaller company, higher risk/reward

Comparative Analysis Report

WallStSmart Research

Bull Case : CCXI

CCXI has a balanced fundamental profile.

Bull Case : EVAC

EVAC has a balanced fundamental profile.

Bear Case : CCXI

The primary concerns for CCXI are Revenue Growth, EPS Growth, Market Cap.

Bear Case : EVAC

The primary concerns for EVAC are P/E Ratio, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

EVAC is growing revenue faster at 0.0% — sustainability is the question.

EVAC generates stronger free cash flow (-121,028), providing more financial flexibility.

Monitor SHELL COMPANIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

EVAC scores higher overall (32/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Churchill Capital Corp XI

FINANCIAL SERVICES · SHELL COMPANIES · USA

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new drugs for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company is headquartered in Mountain View, California.

EQV Ventures Acquisition Corp. II

FINANCIAL SERVICES · SHELL COMPANIES · USA

EQV Ventures Acquisition Corp. II (EVAC) is a special purpose acquisition company (SPAC) strategically spotlighting high-growth enterprises within technology-centric sectors. Leveraging a seasoned management team, EVAC seeks to forge alliances with innovative companies that aim to disrupt traditional market paradigms, thereby creating substantial long-term shareholder value. This investment vehicle offers institutional investors a unique opportunity to engage with and capitalize on transformative trends that are redefining the future business landscape.

Want to dig deeper into these stocks?